摘要
目的探讨survivin、p53、Bcl-2蛋白在非小细胞肺癌(NSCLC)中的表达及与临床病理因素的关系。方法应用免疫组织化学法(SP)检测80例NSCLC肿瘤组织、20例肺良性病变组织中survivin、p53、Bcl-2蛋白表达情况。结果survivin、p53、Bcl-2蛋白在肺癌组织中的阳性表达率分别为61.3%(49/80)、55.0%(44/80)和50.0%(40/80),高于肺良性病变组织中的表达水平(P<0.05)。survivin蛋白的表达在不同的TNM分期之间有显著性差异,但与肺癌组织的细胞类型、分化程度及淋巴结转移无明显关系;P53蛋白的表达在不同的淋巴结转移情况之间以及在不同的TNM分期之间有显著性差异;Bcl-2蛋白的表达在不同的细胞类型之间有显著性差异(P<0.05)。肺癌组织中p53,Bcl-2蛋白与survivin蛋白表达显著相关(P<0.05)。结论survivin、P53、Bcl-2蛋白与肺癌的发生和发展密切相关,并可能起协同作用,其综合检测对肺癌的病情判断和预后评价具有一定价值。
Objective. To investigate the expression of Survivin , P53, Bcl -2 in non small cell lung cancer （NSCLC） and the relationship with clinicopathologic factors. Methods： Expression of the survivin, p53 and Bcl -2 protein was evaluated by immunohistochemical assay in 80 NSCLC tumor samples, 20 inflammatory lung lesions. Results：Expression of survivin , 1353, Bcl - 2 protein in NSCLC were 61.3% （49/80） ,55.0% （44/80） and 50.0% （40/80） respectively, which were higher than that in inflammatory lung lesions （ P 〈 0.05 ） ; The expression of Survivin correlated with TNM stages, and there was no relationship between survivin expression and histologic type , tumor differation and lymphnode metastasis . The expression of P53 correlated with TNM stages and lymphnode metastasis. The expression of Bcl-2 was significantly higher in squamous cancers than in adenocareinomas P 〈0. 05） ; The （expression of survivin correlated with p53, Bcl - 2 expression （ P 〈 0.05 ）. Condusion： Survivin , P53, Bcl - 2 might play synergetic role in the process of carcinogenesis of NSCLC. Determination of their expression might be used to evaluate prognosis.
出处
《现代肿瘤医学》
CAS
2007年第2期193-196,共4页
Journal of Modern Oncology
